Literature DB >> 6714805

Persistent bladder dysfunction after surgical and combination therapy of cancer of the cervix uteri stages Ib and IIa.

G B Kristensen, P C Frimodt-Møller, H K Poulsen, S Ulbak.   

Abstract

The present study is a urologic follow-up investigation of 27 women 17 to 32 months after treatment for carcinoma of the cervix stage Ib and IIa. In 10 women treatment had been exclusively with surgery, while 17 women had received treatment with cesium before surgery. Two patients had major urologic problems with severe stress incontinence and persistent bladder infection, respectively, while 19 had minor urologic complaints on questioning. Nine of twenty-two women (41%) subjected to denervation supersensitivity tests had positive tests. No correlation between a positive denervation test and urologic complaints or findings at cystometrograms could be found. No differences in urologic complaints or results of denervation tests and cystometrograms were found between women treated with surgery exclusively or with cesium before surgery. All treated women had unimpaired renal function judged by serum creatinine and isotopic renography.

Entities:  

Mesh:

Year:  1984        PMID: 6714805     DOI: 10.1016/0090-8258(84)90004-0

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  Voiding dysfunction due to detrusor underactivity: an overview.

Authors:  Marcus J Drake; Jonathan Williams; Dominika A Bijos
Journal:  Nat Rev Urol       Date:  2014-07-08       Impact factor: 14.432

2.  Urodynamics following radical abdominal hysterectomy for cervical cancer.

Authors:  G Ralph; K Tamussino; W Lichtenegger
Journal:  Arch Gynecol Obstet       Date:  1988       Impact factor: 2.344

3.  A comparison of laparoscopic and abdominal radical parametrectomy for cervical or vaginal apex carcinoma and stage II endometrial cancer after hysterectomy.

Authors:  Hongyuan Jiang; Lianxi Qu; Xishi Liu; Keqin Hua; Huan Xu; Sun-Wei Guo
Journal:  JSLS       Date:  2013 Apr-Jun       Impact factor: 2.172

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.